PMID- 26697261
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151223
LR  - 20201001
IS  - 2090-8067 (Print)
IS  - 2042-0072 (Electronic)
VI  - 2015
DP  - 2015
TI  - Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated 
      Thyroid Cancer Treatments.
PG  - 438235
LID - 10.1155/2015/438235 [doi]
LID - 438235
AB  - Background. The aims of this study were to assess patients' preferences to wait 
      or start systemic treatment and understand how patients would make tradeoffs 
      between certain severe adverse events (AEs) and additional months of 
      progression-free survival (PFS). Materials and Methods. Adults in France, 
      Germany, and Spain with a diagnosis of DTC and who have had at least one RAI 
      treatment completed a direct-elicitation question and a discrete-choice 
      experiment (DCE) online. The direct-elicitation question asked respondents 
      whether they would opt out of treatment when their tumor is RAI-R. In the DCE, 
      respondents chose between 12 pairs of hypothetical RAI-R DTC treatment profiles. 
      Profiles were defined by magnitudes of efficacy (PFS) and safety (severe 
      hand-foot skin reaction [HFSR], severe proteinuria, and severe hypertension). A 
      main-effects random-parameters logit model was estimated. Results. 134 patients 
      completed the survey. Most patients (86.6%) opted for treatment rather than "wait 
      and see" decision. Patients placed a greater weight on the risk of severe 
      hypertension than the risk of proteinuria and HFSR. Conclusions. DTC patients 
      showed preference toward treatment for RAI-R DTC over watchful waiting. Patients' 
      concerns about the risk of severe hypertension appeared to have had a greater 
      effect on patients' choice than severe proteinuria or HFSR.
FAU - Mohamed, Ateesha F
AU  - Mohamed AF
AD  - Bayer Healthcare Pharmaceuticals Inc., Whippany, NJ 07981, USA.
FAU - Gonzalez, Juan Marcos
AU  - Gonzalez JM
AD  - RTI Health Solutions, Research Triangle Park, NC 27709, USA.
FAU - Fairchild, Angelyn
AU  - Fairchild A
AD  - RTI Health Solutions, Research Triangle Park, NC 27709, USA.
LA  - eng
PT  - Journal Article
DEP - 20151130
PL  - United States
TA  - J Thyroid Res
JT  - Journal of thyroid research
JID - 101536655
PMC - PMC4677225
EDAT- 2015/12/24 06:00
MHDA- 2015/12/24 06:01
PMCR- 2015/11/30
CRDT- 2015/12/24 06:00
PHST- 2015/09/29 00:00 [received]
PHST- 2015/11/12 00:00 [accepted]
PHST- 2015/12/24 06:00 [entrez]
PHST- 2015/12/24 06:00 [pubmed]
PHST- 2015/12/24 06:01 [medline]
PHST- 2015/11/30 00:00 [pmc-release]
AID - 10.1155/2015/438235 [doi]
PST - ppublish
SO  - J Thyroid Res. 2015;2015:438235. doi: 10.1155/2015/438235. Epub 2015 Nov 30.